#1 Clinical Trials Search in Europe

Travoprost

Travoprost is a medication used in the treatment of glaucoma and ocular hypertension. This article explores various clinical trials that have investigated the efficacy, safety, and tolerability of Travoprost in different formulations and compared to other treatments. These studies aim to improve our understanding of how Travoprost affects intraocular pressure, ocular surface health, and patient comfort.

Table of Contents

What is Travoprost?

Travoprost is a medication used to treat certain eye conditions. It belongs to a class of drugs called prostaglandin analogs. Travoprost is available under various brand names, including Travatan Z and Travatan[1]. It’s important to note that there are different formulations of travoprost, including those with and without preservatives[2].

Conditions Treated by Travoprost

Travoprost is primarily used to treat the following eye conditions:

  • Open-Angle Glaucoma: This is the most common form of glaucoma, where the drainage channels in the eye become clogged over time[4].
  • Ocular Hypertension: This condition is characterized by higher than normal pressure inside the eye[4].
  • Neovascular Glaucoma: A rare type of glaucoma caused by abnormal blood vessel growth in the eye[8].

How Travoprost Works

Travoprost works by reducing the pressure inside the eye, known as intraocular pressure (IOP). It does this by increasing the outflow of fluid (aqueous humor) from the eye. By lowering eye pressure, travoprost helps prevent damage to the optic nerve and potential vision loss[2].

How Travoprost is Administered

Travoprost is typically administered as eye drops. The usual dosage is one drop in the affected eye(s) once daily, often in the evening between 7:00 p.m. and 9:00 p.m[1]. However, some studies have explored different dosing regimens, including multiple doses throughout the day[7]. Always follow your doctor’s instructions regarding the dosage and timing of your medication.

Efficacy of Travoprost

Travoprost has been shown to be effective in lowering intraocular pressure in patients with open-angle glaucoma and ocular hypertension. Studies have compared its efficacy to other similar medications, such as latanoprost (Xalatan)[5]. The effectiveness of travoprost in lowering IOP is typically measured over a 24-hour period[10].

Potential Side Effects

Like all medications, travoprost can cause side effects. Some potential side effects include:

  • Changes to the eye surface (conjunctiva)[5]
  • Dry eye symptoms[1]
  • Redness of the eye (conjunctival hyperemia)[5]
  • Changes in eyelash appearance (length, thickness, color)[5]

Your doctor will monitor you for these and other potential side effects during your treatment.

Comparisons with Other Medications

Several studies have compared travoprost to other glaucoma medications:

  • Travoprost vs. Latanoprost (Xalatan): Some studies have compared the efficacy and side effects of these two medications[1].
  • Preservative-free vs. Preserved Formulations: Research has looked at the differences between travoprost formulations with and without preservatives, such as benzalkonium chloride (BAK)[2].
  • Brand-name vs. Generic Travoprost: Studies have compared the effectiveness of brand-name travoprost to generic versions[4].

Ongoing Research

Research on travoprost is ongoing, with studies exploring various aspects of the medication:

  • Different Dosing Regimens: Some studies are looking at the effects of administering travoprost multiple times per day at lower concentrations[7].
  • Combination Therapies: Research is being conducted on the use of travoprost in combination with other glaucoma medications, such as timolol[10].
  • New Delivery Methods: Studies are exploring new ways to deliver travoprost, such as through intraocular implants[6].
Aspect Details
Primary Use Treatment of open-angle glaucoma and ocular hypertension
Main Outcome Measure Reduction in intraocular pressure (IOP)
Administration Typically one drop in affected eye(s) once daily, often in the evening
Formulations Studied Brand name (e.g., Travatan Z), generic versions, preservative-free formulations
Comparisons Other prostaglandin analogues (e.g., Latanoprost), different concentrations of Travoprost
Secondary Outcomes Ocular surface health, tear film stability, patient comfort and tolerability
Safety Assessments Ocular Surface Disease Index (OSDI), conjunctival hyperemia, corneal staining
Special Considerations Effects of preservatives (e.g., benzalkonium chloride) on ocular surface

FAQ

  • What is Travoprost used for? Travoprost is primarily used to treat open-angle glaucoma and ocular hypertension. It helps lower intraocular pressure (the fluid pressure inside the eye) to prevent damage to the optic nerve and potential vision loss.
  • How is Travoprost typically administered? Travoprost is usually administered as eye drops. In most clinical trials, it is applied once daily, often in the evening between 7:00 p.m. and 9:00 p.m. Some studies have explored different dosing schedules or concentrations.
  • What are some of the side effects associated with Travoprost? Some potential side effects of Travoprost include changes to the ocular surface, such as dry eye symptoms, conjunctival redness, and changes in tear film stability. Studies have also looked at the comfort and tolerability of the medication.
  • How does Travoprost compare to other glaucoma medications? Clinical trials have compared Travoprost to other prostaglandin analogues like Latanoprost (Xalatan). Some studies suggest that Travoprost may be equally effective in lowering intraocular pressure, with potentially different effects on ocular surface health.
  • Are there different formulations of Travoprost? Yes, there are different formulations of Travoprost. Some studies have compared preservative-free versions (like Travatan Z) to those containing preservatives like benzalkonium chloride (BAK). There are also investigations into generic versions of Travoprost compared to brand-name formulations.

Ongoing Clinical Trials on Travoprost

  • Study on Glaucoma Treatment: Comparing Brimonidine, Pilocarpine Nitrate, and Brinzolamide in Patients with Newly Diagnosed Open-Angle Glaucoma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Sweden

Glossary

  • Intraocular Pressure (IOP): The fluid pressure inside the eye. Elevated IOP is a major risk factor for glaucoma and is the primary target for most glaucoma treatments.
  • Ocular Hypertension: A condition where the pressure inside the eye (intraocular pressure) is higher than normal, but without detectable damage to the optic nerve or visual field loss.
  • Open-Angle Glaucoma: The most common form of glaucoma, characterized by gradual blockage of the drainage canals in the eye, resulting in increased intraocular pressure.
  • Prostaglandin Analogue: A class of medications, including Travoprost, used to lower intraocular pressure by increasing the outflow of fluid from the eye.
  • Tear Film Break-Up Time (TBUT): A clinical test that measures the stability of the tear film on the surface of the eye. It is used to assess dry eye symptoms.
  • Ocular Surface Disease Index (OSDI): A questionnaire used to assess symptoms related to dry eye and ocular surface discomfort.
  • Benzalkonium Chloride (BAK): A preservative commonly used in eye drops. Some studies have investigated whether BAK-free formulations may be gentler on the ocular surface.
  • Conjunctival Hyperemia: Redness of the white part of the eye, often assessed as a potential side effect of glaucoma medications.
  • Corneal Staining: A clinical test used to assess the health of the cornea (the clear front part of the eye) by applying a dye and observing any areas of damage or dryness.

References

  1. https://clinicaltrials.gov/study/NCT00799682
  2. https://clinicaltrials.gov/study/NCT01315574
  3. https://clinicaltrials.gov/study/NCT00444665
  4. https://clinicaltrials.gov/study/NCT02796560
  5. https://clinicaltrials.gov/study/NCT00798694
  6. https://clinicaltrials.gov/study/NCT04615403
  7. https://clinicaltrials.gov/study/NCT01298687
  8. https://clinicaltrials.gov/study/NCT00441181
  9. https://clinicaltrials.gov/study/NCT00293761
  10. https://clinicaltrials.gov/study/NCT00444184